Telik, Inc. was set up in 1988 and was reverse merged into privately held MabVax in May 2014.[1] The major drug of the company was TELINTRA, an investigational agent that was in development for the treatment of myelodysplastic syndrome (MDS) and idiopathic chronic neutropenia.[2]
| Industry | Healthcare, Drug Manufacturers - Other |
|---|---|
| Founded | 1988 |
| Headquarters | , |
Key people | Michael M. Wick M.D. ( Chairman, Chief Executive Officer, and President) Wendy K. Wee ( Chief Medical Officer ) (Dec 31, 2012) |
Number of employees | 17 (Dec 31, 2012) |
| Website | telik |
Controversies edit
In 2007, a class action was filed against Telik, Inc., alleging that they made false and misleading statements about the Company’s business and prospects during the Class Period.[3]